



(51) International Patent Classification:

A61K 31/395 (2006.01) A61K 31/42 (2006.01)
A61K 31/4025 (2006.01) A61K 31/33 (2006.01)

(21) International Application Number:

PCT/US2024/060615

(22) International Filing Date:

17 December 2024 (17.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/612,918 20 December 2023 (20.12.2023) US

(71) Applicant: **PERFUSE THERAPEUTICS, INC.**
[US/US]; 611 Gateway Blvd. Suite 910, South San Francisco, California 94080 (US).

(72) Inventors: **GURKAN, Sevgi**; c/o Perfuse Therapeutics, Inc., 611 Gateway Blvd. Suite 910, South San Francisco, California 94080 (US). **GLENDENNING, Angela Dawn**; c/o Perfuse Therapeutics, Inc., 611 Gateway Blvd. Suite 910, South San Francisco, California 94080 (US). **ROMEO, Christopher**; c/o Perfuse Therapeutics, Inc., 611 Gateway Blvd. Suite 910, South San Francisco, California 94080 (US).

(74) Agent: **NGUYEN, Suzanne P.** et al.; Goodwin Procter LLP, 100 Northern Avenue, IP Docketing Dept./7TH FL, Boston, Massachusetts 02210 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS OF PREPARING DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF OCULAR DISEASES

Impact of Edonentan Particle Size on Release




FIG. 1

(57) Abstract: The present disclosure relates to methods of preparing biodegradable ocular implants containing edonentan, or a pharmaceutically acceptable salt thereof. The disclosure also relates to biodegradable ocular implants generally comprising a biodegradable polymer and edonentan, or a pharmaceutically acceptable salt thereof.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*